Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Q1 2026 Earnings Presentation
16 slides from Bristol-myers Squibb's earnings presentation, Apr 30, 2026
Slide 1: Q1 2026 Results
Q1 2026 Results April 30, 2026 Not for Product Promotional Use
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company’s (the the adjusted items or the effects of foreign currency translation, as applicable, and “Company”) future financial results, plans, business development strateg
Slide 3: Q1 2026 Results: Chris Boerner, PhD
Q1 2026 Results Chris Boerner, PhD Board Chair and Chief Executive Officer 3
Slide 4: Q1 2026 Performance
Q1 2026 Performance Growth Portfolio Revenues Key Milestones1 $ in billions +12%; +9% Ex-FX* Achieved multiple clinical & regulatory milestones Iberdomide Mezigdomide Iza-bren $5.6 $6.2 Q1 2025 Q1 2026 Diverse portfolio of growth drivers New indication approvals *See “Forward-Looking Statements and
Slide 5: Significant data expected in 2026…and beyond
Significant data expected in 2026…and beyond* NME registrational data LCM pivotal data Key next wave early-stage data 2026 2026 2026 • Admilparant IPF (ALOFT-IPF) • Cobenfy AD Psychosis (ADEPT-1, 2 & 4) • BCMAxGPRC5D dual-targeting CAR T RRMM • Arlo-cel 4L+ MM (QUINTESSENTIAL) • Sotyktu SLE (POETYK
Slide 6: Keys to enable long-term, sustainable growth
Keys to enable long-term, sustainable growth* Sharpen execution across talent and decision-making to drive our • Drive top-tier R&D early- to –mid stage pipeline productivity Broaden AI application across R&D to optimize operations while improving quality & pace of innovation • Operate with → financ
Slide 7: Q1 2026 Results: David Elkins
Q1 2026 Results David Elkins Executive Vice President and Chief Financial Officer 7
Slide 8: Growth Portfolio represents the majority of revenue
Growth Portfolio represents the majority of revenue Growth Portfolio $ in billions $11.2 $11.5 5.3 5.6 +12% YoY Other Growth Brands1 $5.6 $6.2 +9% Ex-FX* Legacy Portfolio Q1 2025 Q1 2026 Other Mature Brands *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Other Growth Brands:
Slide 9: Q1 2026 Oncology product summary
Q1 2026 Oncology product summary Global Net Sales1 Opdivo $M YoY % Ex-FX* % • Remains an important contributor to the Growth Portfolio and continues to deliver value to patients $2,146 (5%) (8%) Qvantig $651 +4% +2% • Continued global growth is driven by meaningful convenience to patients and health
Slide 10: Q1 2026 Hematology product summary
Q1 2026 Hematology product summary Global Net Sales1 Reblozyl $M YoY % Ex-FX* % • Growth driven by continued global demand across MDS-associated anemia $555 +16% +15% • Established strong brand momentum, with the 2 predominant share of business from 1L MDS-anemia $513 (22%) (22%) Breyanzi $411 +56%
Slide 11: Q1 2026 Cardiovascular & Immunology product summary
Q1 2026 Cardiovascular & Immunology product summary Global Net Sales (Cardiovascular) Camzyos $M YoY % Ex-FX* % • Continued strong global demand and market penetration in oHCM $4,137 +16% +13% • Strong launch momentum outside the U.S. Eliquis $314 +97% +94% • Continued U.S. demand growth and market
Slide 12: Q1 2026 Neuroscience product summary
Q1 2026 Neuroscience product summary Global Net Sales Cobenfy $M YoY % Ex-FX* % • Steady growth trajectory expected near term 1 • Opportunity to improve patient experience through $118 +11% +7% prescriber education emphasizing optimized dose utilization $56 +107% +107% • Focus on expanding both brea
Slide 13: Q1 2026 Financial Performance
Q1 2026 Financial Performance GAAP US GAAP Non-GAAP Non-GAAP * $ in billions, except EPS Q1 2026 Q1 2025 Q1 2026 Q1 2025 Total Revenues, net 11.5 11.2 11.5 11.2 Gross Margin %1 70.2% 72.9% 70.3% 73.1% Operating Expenses2 4.3 3.8 3.9 3.8 Acquired IPR&D 0.1 0.2 0.1 0.2 Amortization of Acquired Intangi
Slide 14: Strategic approach to Capital Allocation
Strategic approach to Capital Allocation Cash flow from Operations $B Business • Pursue opportunities and partnerships to diversify Development portfolio & strengthen long-term outlook $6.3 $3.9 Balance Sheet • Strong balance sheet affords financial flexibility Strength • Maintain strong investment-
Slide 15: 2026 Guidance
2026 Guidance* Non-GAAP1 Key Highlights February (Prior) April (Reaffirmed) • FY revenue tracking toward the upper end of our established guidance range: Total FY Revenues ~$46.0 - $47.5B No change (Reported & Ex-FX) • Continued Growth Portfolio strength Gross Margin % ~69-70% No change • 12% to 16%
Slide 16: Q1 2026 Results Q&A
Q1 2026 Results Q&A Chris Boerner, PhD David Elkins Adam Lenkowsky Cristian Massacesi, MD Board Chair, Executive VP, Executive VP, Executive VP, Chief Executive Officer Chief Financial Officer Chief Commercialization Chief Medical Officer, Officer Global Drug Development
Bristol-Myers Squibb Company — Q1 2026 Earnings Presentation on 6ix